PDCD1 and neoplasm: The PHAEDRA study showed promising activity of durvalumab in 35 patients with advanced dMMR/MSI-H endometrial cancer and found an ORR of 47% (95% CI, 32–63%), consistent with previous trials evaluating the efficacy of anti-PD1 in dMMR/MSI-H tumours [2, 18–20].